摘要
Dear editor,Sodium glucose co-transporter 2 inhibitors(SGLT2I)reduce the majority of reabsorption of glucose in the proximal tubules,which reduces blood glucose levels by allowing excretion of excess glucose in the urine.[1]By inhibiting glucose reabsorption,they increase the osmotic pressure of urine resulting in diuresis which can cause a reduction of blood pressure.[2]Fortunately,as these drugs are not directly implicated in altering glucose metabolism or causing insulin secretion,SGLT2I monotherapy does not result in severe hypoglycemia.